Semaglutide News

A new study has found that Semaglutide, a drug commonly used for diabetes and weight loss, slows signs of ageing and extends the lifespan of mice.

A study published in Nature found that late-life semaglutide treatment in female mice slowed ageing and extended their lifespan. The treatment improved physiolo

GLP-1 weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound are effective even at low starter doses. These drugs are initially prescribed at a low dose

The government plans to introduce new regulations requiring pharmaceutical companies to differentiate between biologics and synthetics to clarify ambiguity arou

Lupin believes the GLP-1 market may be smaller than anticipated and is planning its next generation of weight-loss drugs, including fortnightly bofenglutide and

The Centre has highlighted concerns regarding semaglutide rules in India's weight-loss drug market, where manufacturers currently rely on internal or foreign pr

GLP-1 drugs, typically used for obesity, are showing promise in treating polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder previously known a

The Delhi High Court has mandated Sun Pharma Laboratories to seek its approval before launching semaglutide tablets, following a patent infringement plea by Nov

The Delhi High Court has ordered Sun Pharma to obtain judicial approval before launching semaglutide tablets, following a patent infringement lawsuit filed by N

A recent clinical trial found that individuals with alcohol use disorder who took oral semaglutide, a daily GLP-1 pill, showed significant improvements compared

Sun Pharma has received approval for Semaglutide in Brazil, entering a market for injectable semaglutide estimated at around $413 million.

Cipla is prioritizing its tirzepatide brand Yurpeak in the Indian obesity market, which has become the second-largest GLP-1 product since its launch. The compan

Dr. Reddy's Laboratories shares dropped nearly 3% due to investor concerns over a delayed exclusivity benefit for its Semaglutide opportunity. A senior VP at Ge

Dr Reddy's aims to resume semaglutide supplies by November after identifying and resolving quality issues related to its active pharmaceutical ingredient (API).

Emcure Pharmaceuticals has received CDSCO approval to market its brand Poviztra for the treatment of fatty liver (metabolic dysfunction-associated steatohepatit

India's drug regulator has approved Novo Nordisk's obesity drug Wegovy for the treatment of MASH, a severe form of fatty liver disease, following a committee re

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic ver

The widespread use of GLP-1 medications like Ozempic is significantly impacting the wedding dress industry, as bridal designers must now accommodate rapid weigh

The Semaglutide situation has exposed systemic weaknesses in India's pharmaceutical industry, potentially proving costly for the country's generics sector.

Despite an increase in generic semaglutide options, recent data indicates a shift in market dynamics, impacting sales forecasts and patient onboarding rates for

Dr Reddy's shares have crashed 9% in two days after the company delayed semaglutide supplies due to a quality-related API issue, leading brokerages to slash tar

Dr Reddy's Laboratories has paused semaglutide injection supplies until at least October due to unspecified impurities found during manufacturing scale-up, lead

Dr. Reddy's ने गुणवत्ता संबंधी चिंताओं के कारण सेमाग्लूटाइड की आपूर्ति रोक दी है, जिससे उसके शेयर गिर गए हैं, और टॉरेंट ने भी उत्पाद वापस मंगा लिया है।

Dr. Reddy's गुणवत्ता संबंधी समस्या के कारण सेमाग्लूटाइड की आपूर्ति में देरी करेगा, जिससे उसके शेयर प्रभावित हुए हैं; सेमाग्लूटाइड नोवो नॉर्डिस्क की वेगोवी और ओज